BioPharm International
February 01, 2016
Upstream Processing
28
2
The authors review the status of expression of antibodies in microbial hosts and present the recent advances in the production of aglycosylated antibodies in bacteria.
February 01, 2016
28
2
Rapid methods to test CAR-T therapies for potential contamination are on the horizon.
February 01, 2016
Regulatory Beat
28
2
FDA and industry see progress and challenges in bringing cutting-edge medicines to patients.
February 01, 2016
Perspectives on Outsourcing
28
2
Heightened global uncertainty could slow bio/pharma development activity.
February 01, 2016
Cover Story
28
2
Time and sensitivity are essential for analytical technologies in all phases of biopharma development.
February 01, 2016
From the Editor
28
2
Report: Biologics contribute to rebirth of biopharma innovation.
February 01, 2016
Features
28
2
Understanding of the risks associated with FMEA is crucial in lot release testing.
February 01, 2016
Peer-Reviewed Research
28
2
The recognition that microbial artifacts are capable of modulating the mammalian immune system is an emerging view of biologic drug contamination control testing.
February 01, 2016
Features
28
2
The authors describe the impact of the knocking of the pgi gene of the wild type MG1655 strain on the growth kinetics of plasmid-free and plasmid-bearing cells.
February 01, 2016
Features
28
2
In this article, the author reviews some of the techniques that can yield valuable information on protein stability, focusing specifically on protein aggregation. Emphasis is placed on the enhanced information made available when technologies are used orthogonally, and the alignment of different approaches with specific stages of the biopharmaceutical development workflow.
February 01, 2016
Issue PDF
28
2
Click the title above to open the BioPharm International February 2016 issue in an interactive PDF format.